Iberdomide
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Iberdomide, sold under the brand name Zenbexus, is an anti-cancer medication used for the treatment of multiple myeloma. It is a cereblon-modulating protein degrader and a thalidomide analog. . It is taken by mouth. Iberdomide was approved for medical use in the United States in August 2026.
Iberdomide, sold under the brand name Zenbexus, is an anti-cancer medication used for the treatment of multiple myeloma. It is a cereblon-modulating protein degrader and a thalidomide analog. . It is taken by mouth. Iberdomide was approved for medical use in the United States in August 2026. Efficacy was evaluated in EXCALIBER-RRMM (NCT04975997), a two-stage, randomized, multi-center, open-label trial in adults with relapsed or refractory multiple myeloma who had previously received one or two prior lines of therapy. People who had disease refractory to prior anti-CD38 monoclonal antibody therapy, or to prior bortezomib were excluded. A total of 939 participants were randomized to one of three dose levels of iberdomide in combination with daratumumab and hyaluronidase and dexamethasone (IberDd) or to daratumumab and hyaluronidase, bortezomib and dexamethasone (DVd) in stage 1 (n=279); or to iberdomide 1 mg in combination with daratumumab and hyaluronidase and dexamethasone (Dd) or DVd in stage 2 (n=660).
Text derived from https://en.wikipedia.org/w/index.php?oldid=1376990657 under CC BY-SA 4.0; modifications have been made.